References
- Sica D. A. Are current strategies for treating hypertension effective?. J Clin Hypertens (Greenwich) 2003; 5((3 Suppl 2))23–32
- Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252
- Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187
- Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., Prospective Studies Collaboration. Age‐specific relevance of usual blood pressure to vascular mortality: A meta analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913
- Marques‐Vidal P., Tuomilehto J. Hypertension awareness, treatment and control in the community: Is the “rule of halves” still valid?. J Hum Hypertens 1997; 11: 213–220
- Antikainen R. L., Moltchanov V. A., Chukwuma C., Sr., Kuulasmaa K. A., Marques‐Vidal P. M., Sans S., et al. Trends in the prevalence, awareness, treatment and control of hypertension: The WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 2006; 13: 13–29
- Neutel J. M., Smith D. H., Weber M. A. Low‐dose combination therapy: An important first‐line treatment in the management of hypertension. Am J Hypertens 2001; 14: 286–292
- Bakris G. L. The importance of blood pressure control in the patient with diabetes. Am J Med 2004; 30S–38S
- Sica D. A. Rationale for fixed‐dose combinations in the treatment of hypertension. The cycle repeats. Drugs 2002; 62: 443–462
- Pool J., Oparil S., Hedner T., Glazer R., Oddou‐Stock P., Hester A. Dose‐responsive antihypertensive efficacy of Valsartan, a new angiotensin II‐receptor blocker. Clin Ther 1998; 20: 1106–1114
- Benz J. R., Black H. R., Graff A., Reed A., Fitzsimmons S., Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension: A multiple dose, double‐blind, placebo‐controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861–866
- Mallion J. M., Carretta R., Trenkwalder P., Martinez J‐F., Tykarski A., Teitelbaum I., et al. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press 2003; 12((Suppl 1))36–43
- O'Brien E., Waeber B., Parati G., Staessen J., Myers M. G. Blood pressure measuring devices: Recommendations of the European Society of Hypertension. BMJ 2001; 322: 531–536
- Pool J., Glazer R., Weinberger M., Alvarado R., Huang J., Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double‐blind, placebo‐controlled study followed by long‐term combination therapy in hypertensive adults. Clin Ther 2007; 29: 61–73
- Ruilope L. M., Malacco E., Khder Y., Kandra A., Bonner G., Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study. Clin Ther 2005; 27: 578–587